Springvale, ME, United States of America

Jim Heimbach

USPTO Granted Patents = 1 

 

Average Co-Inventor Count = 3.0

ph-index = 1


Company Filing History:


Years Active: 2020

Loading Chart...
Loading Chart...
1 patent (USPTO):Explore Patents

Title: Jim Heimbach: Innovator in Biopharmaceutical Processing

Introduction

Jim Heimbach is a notable inventor based in Springvale, Maine, who has made significant contributions to the field of biopharmaceutical processing. With a focus on improving equipment used in this industry, Heimbach has developed innovative solutions that enhance the efficiency and effectiveness of biopharmaceutical production.

Latest Patents

Heimbach holds a patent for "Reactor Surface Finish Remediation," which addresses the challenges associated with biopharmaceutical processing equipment, such as reactor vessels and stainless steel surfaces. This patent outlines methods for determining and improving the surface roughness of equipment that comes into contact with proteinaceous processing materials. Specifically, it emphasizes the importance of maintaining a pre-commissioning surface roughness of greater than about 20 Ra Max (μin) to ensure optimal performance.

Career Highlights

Throughout his career, Heimbach has worked with prominent companies in the biopharmaceutical sector, including Lonza Inc. and Glaxo Group Limited. His experience in these organizations has allowed him to gain valuable insights into the industry's needs and challenges, further informing his innovative approaches.

Collaborations

Heimbach has collaborated with talented professionals in the field, including Michael Mietzner and Andrew Mitchell Harris. These partnerships have contributed to the development of his patent and have fostered a collaborative environment for innovation.

Conclusion

Jim Heimbach's contributions to biopharmaceutical processing through his innovative patent demonstrate his commitment to advancing the industry. His work not only enhances equipment performance but also reflects the importance of continuous improvement in biopharmaceutical manufacturing.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…